This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Lundbeck undertakes no duty to update forward-looking statements.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with products that are prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the products are currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the U.S., prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.
Lundbeck at a glance

**History**
- Lundbeck was founded by Hans Lundbeck in 1915 in Copenhagen

**Ownership**
- Largest shareholder is the Lundbeck Foundation, which annually grants DKK ~500 million to research

**Specialized in brain health**
- ~70 years of expertise in treatments of brain diseases
- Among the first to develop and market antipsychotics

**1915**

**69%**

**70 years**

**2019 Revenue**
- ~58% generated in North America
- China 2nd largest market

**DKK 17.0bn**
(=~$2.5bn)

**Global presence**
- Headquartered in Denmark
- 50+ countries

**Five strategic brands (55% of rev.)**

Lundbeck
Diverse portfolio across products and regions with geographical footprint well aligned to global CNS market

Lundbeck product diversity
Sales by product (Q1 2020)

Lundbeck geographic split
Sales by region (Q1 2020)

Global CNS market split (1)
Sales by region (FY 2018)

1) IQVIA 2018 Data
**Strong financial performance in Q1 2020**

- Revenue grew due to strongly increased demand of medicines
- Growth was partly due to increase in the real demand of products and partly due to inventory increases driven by the COVID-19 pandemic
- Vyepti approved and launched in the U.S. – submitted for approval in Canada, Australia and Switzerland
- Financial guidance for 2020 maintained

**HIGHLIGHTS AND STRATEGY UPDATE**

- **Revenue**
  - DKK 4,564 million
  - +8%

- **Strategic brands**
  - DKK 2,680 million
  - +35%

- **Core EBIT**
  - DKK 1,357 million
  - -4%

- **Core EBIT margin**
  - 29.7%
  - -3.6pp
Lundbeck’s revenue shows solid growth momentum, earnings impacted by Vyepti launch costs

- Revenue continues to grow as U.S. neurology products are being washed out; the quarter had a positive impact from stocking as a consequence of the COVID-19 pandemic

- In the quarter, core EBIT-margin reaches 29.7% compared to 33.3% the previous year despite investments in commercial infrastructure and added operational costs related to Lundbeck Seattle
Update on COVID-19

Lundbeck’s priorities have been and still are the health and safety of our employees, product supply to ensure patients’ access to medicine and business continuity.

Q1 2020:
- Safeguarding product supply, production, logistics and operations
- Positive impact from stocking especially in Europe and the U.S. Some weakness in China
- Several clinical programmes delayed
- Extensive use of technology to support work from home/increased digitalization

Current business:
- Continued strong momentum for strategic brands
- China reopening and moving towards normal
- Encouraging interest in Vyepti
- Impact on patient recruitment and new site activation in clinical trials
Vyepti launch update – very early days, but encouraging interest

• Vyepti was made available to patients on 6 April 2020, and the first patients received therapy on 7 April

• Several key clinics received Vyepti already in the first week and many more since

• Phased launch approach starting with virtual HCP engagement. Customer facing engagement will commence when appropriate

• Encouraging interest in enrolling in the Vyepti Connect\(^1\) and Vyepti Go\(^2\)

• Several payers have issued coverage policies, e.g. Anthem, Highmark, BCBS of NJ, Premera, etc.

---

1) Access and reimbursement support program. 2) Patient support program
Maximising the value of Vyepti

- RELIEF study continues to randomize patients. Conclude Q4.20
- Indication expansion in cluster headache planned to start Q4.20
- European market access study (phase IIIb) to start mid-2020
- First phase of Japanese PK/PD study finalized as planned; development strategy for Asia progressing
- Further indication expansion in planning

Submissions
- Canada: Expected approval Q1 2021
- Australia: Expected approval Q2 2021
- Switzerland: Expected approval Q4 2021
Robust financial performance in Q1 2020 - Investments in new products and reduced exposure to generic erosion

Revenue
- Continued strong momentum for strategic brands
- Positive impact from patient refilling and stocking due to COVID-19 pandemic
- Continued erosion of mature U.S. neurology franchise

Margins
- Gross margin in line with expectations
- Operational costs increased as expected and impacted by impairment of foliglurax product rights (EUR 100m)
- Core tax rate 22.8% vs. 24.5% in Q1 2019

### FINANCE – Q1 2020 PERFORMANCE

<table>
<thead>
<tr>
<th></th>
<th>DKKm</th>
<th>Q1 2020</th>
<th>Δ% y/y</th>
<th>FY 2019</th>
<th>Δ% y/y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>4,564</td>
<td>8%</td>
<td>17,036</td>
<td>(6%)</td>
<td></td>
</tr>
<tr>
<td>Gross margin</td>
<td>82.4%</td>
<td>1.9pp</td>
<td>80.1%</td>
<td>-0.8pp</td>
<td></td>
</tr>
<tr>
<td>Operational expenses</td>
<td>3,391</td>
<td>53%</td>
<td>9,529</td>
<td>+2%</td>
<td></td>
</tr>
<tr>
<td>Other operating items, net</td>
<td>(30)</td>
<td>-</td>
<td>(514)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>EBIT</td>
<td>338</td>
<td>(72%)</td>
<td>3,608</td>
<td>(32%)</td>
<td></td>
</tr>
<tr>
<td>EBIT margin</td>
<td>7.4%</td>
<td>-20.9pp</td>
<td>21.2%</td>
<td>-8.1pp</td>
<td></td>
</tr>
<tr>
<td>Core EBIT</td>
<td>1,357</td>
<td>(4%)</td>
<td>4,976</td>
<td>(19%)</td>
<td></td>
</tr>
<tr>
<td>Core EBIT margin</td>
<td>29.7%</td>
<td>-3.6pp</td>
<td>29.2%</td>
<td>-4.8pp</td>
<td></td>
</tr>
<tr>
<td>Net financials</td>
<td>(97)</td>
<td>-</td>
<td>(127)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Effective tax rate</td>
<td>37.5%</td>
<td>-10.5pp</td>
<td>23.4%</td>
<td>-2.7pp</td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>0.76</td>
<td>(83%)</td>
<td>13.42</td>
<td>(32%)</td>
<td></td>
</tr>
<tr>
<td>Core EPS</td>
<td>4.89</td>
<td>(11%)</td>
<td>19.46</td>
<td>(18%)</td>
<td></td>
</tr>
</tbody>
</table>
Revenue up 22% excluding sales from U.S. neurology products* currently exposed to impact from LOE

- Strategic brands up 35% in the quarter
- Excluding U.S. neurology products* with LOE, revenue up by 22%
- Mature brands stable
- Focus on maximizing existing brands has successfully driven strong growth
- Future growth less impacted by decline in U.S. neurology products
Lundbeck’s four strategic brands added DKK 701 million in additional revenue in Q1 2020

- **Strategic brands**: Up 35% (32% in L.C.) to DKK 2,680 million representing 59% of total revenue
- **Rexulti/Rxulti**: Up 48% to DKK 713 million
- **Brintellix/Trintellix**: Up 36% to DKK 817 million
- **Abilify Maintena**: Up 33% to DKK 612 million
- **Northera**: Up 24% to DKK 538 million
- **Vyepti**: Phased launch commenced in April 2020 in the U.S.
Abilify Maintena continues its robust growth but also benefitting from inventory increases in the U.S. following COVID-19

- Grew 33% (30% in L.C.) to DKK 612 million in Q1 2020
- Continued solid traction in value share gains
  - >25%: Australia, Canada, Italy, Switzerland and UK
  - >20%: Denmark, Finland, France, Norway, Spain and Sweden
- LAI market continues double-digit growth to USD 1.4bn (Q1.2020)
- Abilify Maintena’s share of the LAI market is 19.5% compared to 16.6% in Q1.2019

---

1) Reported net sales of atypical LAIs

*) Lundbeck's share of revenue
Brintellix/Trintellix continues its significant growth momentum

- Grew 36% (34% in L.C.) to DKK 817 million in Q1 2020
- Continued solid traction in value share gains
  - >10%: Finland, France, Italy, Norway, Sweden and the U.S.
  - >7%: Canada, Denmark, Spain
  - >4%: Australia, Mexico, Switzerland and Turkey
- In the U.S., volume is up 15% y/y in Q1 2020
  - U.S. value share of 22.6%
- Trintellix launched in Japan in November 2019

1) IQVIA, February 2020. 2) Symphony Health (c.f. Bloomberg)
Northera shows solid growth in sales and demand

- Grew 24% (20% in L.C.) to DKK 538 million in Q1 2020
- Volume is up 8%\(^1\) compared to Q1 2019
- Northera impacted by normal quarterly fluctuations driven by e.g. seasonality and pharmacies’ buying pattern
- Lundbeck only promotes Northera in the U.S.

\(^1\) Symphony Health (c.f. Bloomberg)
Rexulti shows significant growth mainly driven by demand, but is also benefitting from inventory increases in the U.S.

- Grew 48% (43% in L.C.) to DKK 713 million in Q1 2020
- In the U.S., volume is up 22% y/y in Q1 2020
- Continued solid traction in value share gains
  - >9%: USA
  - >4%: Mexico
  - >2%: Australia, Canada, Mexico, Saudi Arabia
- The Brazilian Regulatory Agency has approved Rexulti as adjunctive treatment in MDD

1) Symphony Health (c.f. Bloomberg). 2) IQVIA, February 2020

*) Lundbeck’s share of revenue
All regions have returned to solid growth

- **Strong improvement in both growth and profitability in Europe**
- **International Markets** shows solid growth driven by e.g. Australia and Japan
  - **North America** impacted by generic erosion, mainly Onfi
    - Growth of 21% excluding Onfi
  - Largest markets are the U.S., China, Canada, Spain, Italy, France and Japan constituting >70% of sales#

---

### Regional growth
(Q1 2020 - DKKm)
- North America: +10%
- International Markets: +16%
- Europe: +9%

### Sales by region#
(Q1 2020)
- North America: 53%
- International Markets: 27%
- Europe: 20%

#) Excluding Other revenue and effects from hedging
Solid growth in all three regions

- Strategic brands up 36% to DKK 1,912m
- 32% growth ex. Onfi, Sabril and Xenazine
- Vyepti will add modestly to growth in 2020

- Strategic brands up 47% to DKK 252m
- Cipralex/Lexapro continues to perform well

- Strategic brands up 28% to DKK 516m
- Abilify Maintena and Brintellix show strong growth in major markets and across other European markets
**Solid financial position**

### Selected cash flow figures

<table>
<thead>
<tr>
<th>DKKm</th>
<th>Q1 2020</th>
<th>Q1 2019</th>
<th>FY 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash flows from operating activities</td>
<td>188</td>
<td>837</td>
<td>2,609</td>
</tr>
<tr>
<td>Cash flows from investing activities</td>
<td>(68)</td>
<td>(63)</td>
<td>(7,755)</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>120</td>
<td>774</td>
<td>(5,146)</td>
</tr>
<tr>
<td>Cash flows from financing activities</td>
<td>(836)</td>
<td>(2,418)</td>
<td>4,548</td>
</tr>
<tr>
<td>Net cash flow for the period</td>
<td>(716)</td>
<td>(1,644)</td>
<td>(598)</td>
</tr>
</tbody>
</table>

### Selected balance sheet figures

<table>
<thead>
<tr>
<th>DKKm</th>
<th>31.03.2020</th>
<th>31.12.2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intangible assets</td>
<td>22,652</td>
<td>23,399</td>
</tr>
<tr>
<td>Total assets</td>
<td>34,867</td>
<td>35,757</td>
</tr>
<tr>
<td>Equity</td>
<td>14,074</td>
<td>14,554</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>12,928</td>
<td>10,923</td>
</tr>
<tr>
<td>Current liabilities</td>
<td>7,865</td>
<td>10,280</td>
</tr>
<tr>
<td>Cash, bank balances and securities</td>
<td>2,287</td>
<td>3,012</td>
</tr>
<tr>
<td>Interest-bearing debt</td>
<td>(9,638)</td>
<td>(9,578)</td>
</tr>
<tr>
<td>Net debt</td>
<td>(7,351)</td>
<td>(6,566)</td>
</tr>
</tbody>
</table>

- **Dividend pay-out, net:** DKK 815m for 2019 or DKK 4.10 per share paid in March 2020
- **Net debt:** Net debt position of around DKK 6 billion expected by the end of 2020
- **Net debt/EBITDA:** Expected to reach 1.5x by end of 2020 vs. 1.4x by the end of 2019
2020 guidance maintained

- Continued strong growth for strategic brands
- Increased uncertainty following the COVID-19 pandemic
- Substantial investments in launch and R&D activities for Vyepti
- Expected effects from hedging is a loss of around DKK 150 - 200 million
- Expected net financial expenses of DKK 300-400 million
- Financial guidance based on currency levels end-April 2020*

<table>
<thead>
<tr>
<th>2020 financial guidance</th>
<th>FY 2019 actual</th>
<th>FY 2020 guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>DKK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>17,036m</td>
<td>17.4 – 18.0bn</td>
</tr>
<tr>
<td>EBITDA</td>
<td>4,823m</td>
<td>3.9 – 4.4bn</td>
</tr>
<tr>
<td>Core EBIT</td>
<td>4,976m</td>
<td>3.5 – 4.0bn</td>
</tr>
<tr>
<td>EBIT</td>
<td>3,608m</td>
<td>1.4 – 1.9bn</td>
</tr>
</tbody>
</table>

*) Lundbeck’s main trading currencies are the USD, CNY, CAD and JPY. The financial guidance is based on the current hedging rates for our main currencies; i.e. USD/DKK (6.57), JPY/DKK (0.0625), CAD/DKK (4.99) and CNY/DKK (0.95)
**Project status**

All studies heavily impacted by COVID-19

Intensive LCM programme for **Rexulti** continues

Continued emphasize on **Lundbeck La Jolla research platform** to reveal full potential of serine hydrolases

- Focused effort for **Lu AG06466** in exploratory clinical studies in psychiatry and neurology, such as MS spasticity and focal epilepsy

No further development in **foliglurax** program

### Project status table

<table>
<thead>
<tr>
<th>Project</th>
<th>Area</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Filing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eptinezumab (anti-CGRP mAb)</td>
<td>Migraine prevention</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brexpiprazole</td>
<td>Agitation in Alzheimer’s disease</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>~2021</td>
</tr>
<tr>
<td>Brexpiprazole</td>
<td>PTSD</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>≥2023</td>
</tr>
<tr>
<td>Brexpiprazole</td>
<td>Borderline Personality Disorder</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>≥2025</td>
</tr>
<tr>
<td>Lu AF11167 (PDE 10 inhibitor)</td>
<td>Schizophrenia</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>≥2025</td>
</tr>
<tr>
<td>Aripiprazole 2-month injectable</td>
<td>Schizophrenia+bipolar I disorder</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>~2021</td>
</tr>
<tr>
<td>Lu AF82422 (alpha-synuclein mAb)</td>
<td>Synucleinopathies</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>&gt;2025</td>
</tr>
<tr>
<td>Lu AF28996 (D1/D2 agonist)</td>
<td>Parkinson’s disease</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>&gt;2025</td>
</tr>
<tr>
<td>Lu AG06466 (MAGLI)</td>
<td>Neurology/psychiatry</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>&gt;2025</td>
</tr>
<tr>
<td>Lu AF88434 (PDE1B inhibitor)</td>
<td>Cognitive dysfunction</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>&gt;2025</td>
</tr>
<tr>
<td>Lu AG02222 (PACAP mAb)</td>
<td>Migraine</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>&gt;2025</td>
</tr>
<tr>
<td>Lu AF87908 (Tau mAb)</td>
<td>Tauopathies</td>
<td></td>
<td>✗</td>
<td>✗</td>
<td>&gt;2025</td>
</tr>
</tbody>
</table>
Brintellix/Trintellix: **COMPLETE** study finalized with significant reduction in emotional blunting in MDD

- Nearly half of patients treated with SSRIs or SNRIs report suffering from ‘blunted emotions’
- Blunted emotions have real functional consequences for patients’ social, family and work lives
- Evaluated the effectiveness of 10–20 mg/day vortioxetine on emotional blunting in patients with MDD and a partial response to SSRI / SNRI

**Key findings of the COMPLETE study:**
- 50% report absence of emotional blunting after 8 weeks of treatment with vortioxetine 10 or 20 mg. Highly statistically significant
- Significant effect on emotional blunting observed already after 1 week of treatment
- Improvement in emotional blunting was followed by improvement in overall functioning, motivation and energy (mental and physical)

**RESEARCH AND DEVELOPMENT**

MDD: Major Depressive Disorder. SSRI: Selective serotonin reuptake inhibitor; SNRI: Serotonin–norepinephrine reuptake inhibitors
Migraine prevention represents a large and under served market

Addressable population (major countries\(^1\))

~134m – Migraine prevalence
~41m – Diagnosed patients (30%)
~18m – Eligible for prevention (43%)
~9m – Currently on prophylactic treatment

Migraine is divided into two major categories, episodic and chronic depending on the frequency of headaches

1-14 headache days per month

>14 headache days per month

Episodic | Episodic eligible for preventive Tx | Chronic

<4 migraine days per month

>4 migraine days per month

≥8 migraine days per month

\(^1\) Decision Resource, DRG 2018 Migraine Market Report. Covers G7+China
Ready to launch Vyepti in the U.S.

Migraine prevention market: $13.9m^{1, 2}$

- **47%** Untreated, undiagnosed people with migraine
- **Diagnosed, untreated**
- **Diagnosed & preventively treated**

### Breakout of 27% treated group

<table>
<thead>
<tr>
<th>Preventive Treatment</th>
<th>% of Use$^3$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Botox</td>
<td>10%</td>
</tr>
<tr>
<td>Anti-CGRPs</td>
<td>5%</td>
</tr>
<tr>
<td>Other preventive treatments (Topiramates, beta-blockers, other anti-seizures, amitryptaline)</td>
<td>85%*</td>
</tr>
</tbody>
</table>

As of 9/13/19 IQVIA Xponent PlanTrak data$^4$

- ~200K patients are currently on anti-CGRP therapy
- ~25-30K new patients enter the anti-CGRP market

* Some patients are on combo therapy such as anti-CGRP + topiramates. For purpose of this analysis, patients on multiple therapies are deduped.

1) 2018 DRG Migraine Market Landscape & Forecast. 2) Lipton 2007; 13.9M= 62% 4+ Migraines, 38% 15+. 3) 2019 Truven Health Analytics. 4) IQVIA Xponent PlanTrak 9/13/19
Two large pivotal studies including ~2,000 patients demonstrated sustained efficacy and good tolerability

**Promise 1**
**in Episodic Migraine Patients**
(N=888)
- **Primary endpoint**: Change from baseline in MMDs over weeks 1-12
- Baseline: ~9 migraine days/month
- 30mg, 100mg, 300mg or placebo
- Up to 4 quarterly infusions

**Promise 2**
**in Chronic Migraine Patients**
(N=1,072)
- **Primary endpoint**: Change from baseline in MMDs over weeks 1-12
- Baseline: ~16 migraine days/month
- 100mg, 300mg or placebo
- Up to 2 quarterly infusions

**Powerful**
≥50%, ≥75% and 100% reductions in migraine days

**Fast**
Onset of prevention
Day One post-infusion

**Sustained**
for 3 months following a single administration and sustained or further increased with subsequent infusions

**Meaningful**
Significant improvement in patient reported outcome (HIT-6)
**PROMISE 1**: A phase III study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraine

- Eptinezumab reaching statistical significance for the primary and all key secondary endpoints
- Migraine day prevalence dropped over 50% on Day 1 and reduction was sustained through Day 28
- Subjects experienced significantly fewer days with migraine
- Responder rates further improved with subsequent infusions for the 300 mg dose group

1) Clinicaltrials.gov ID: NCT04082325
Eptinezumab achieved meaningful reductions in migraine activity as early as Day 1 that were sustained through Week 12: results from PROMISE 2 phase III trial in chronic migraine

- In subjects with chronic migraine beginning on the 1st day post-infusion, a single infusion of eptinezumab significantly reduced migraine activity for 3 months

- >61% of subjects’ migraine days were reduced by ≥75% and, on average, 38% experienced a ≥75% reduction over 3 months

- The % of subjects with a migraine on Day 1 was reduced >50% following eptinezumab infusion and the reduction was sustained for 1 month

Day 1 Reductions from baseline in percentages of subjects with a migraine maintained on average through 28 Days

- At Day 1 following eptinezumab infusion, migraine risk was reduced by 52%

≥75% Migraine Responder Rates (RR) following a single administration

- An average of 38% of subjects treated with eptinezumab achieved a ≥75% reduction in monthly migraine over 3 months

- This RR benefit was obtained as early as Weeks 1–4 and was maintained through Weeks 9–12

Clinicaltrials.gov ID: NCT02974153. Presented at 2018 AAN Annual Meeting, April 21–27, Los Angeles, CA
HIT-6 is a widely used patient-reported outcome measure in headache and migraine research

- General measure of impact of headache on daily life
- Six-item scale (severe pain, limits daily activities, lie down, too tired, felt fed up or irritated, limits concentration)
- Scoring:
  - ≥60: severe impact
- A reduction in total HIT-6 score of ≥6 points has been reported to be clinically meaningful
- 300 mg significant at \( p < 0.0001 \)

**RELIEF-study: Starting migraine prevention during attack**

- Enrollment commenced in November 2019 (n=450 subjects who are candidates for preventive therapy)*

- Single-dose study with a 4-week follow-up period

- Study planned to complete by the end of 2020

**Eptinezumab has...**

- ...throughout its development programme for preventive migraine treatment, consistently demonstrated a reduction in the percentage of subjects with a migraine on Day 1 after infusion, a measure that provides information on the early onset of efficacy for the preventive treatment of migraine

- ...the potential to impact ongoing migraine attacks and at the same time, provide a sustained preventive benefit

*) [Clinicaltrials.gov ID: NCT04152083](https://clinicaltrials.gov/ct2/show/NCT04152083)
VYEPTI - EPTINEZUMAB

Success for Vyepti is a marathon, not a sprint

Other indications currently under evaluation; clinical activity to commence by the end of 2020
- Cluster headache
- Medication overuse headache
- Post-concussion headache
- Other pain syndromes
Third study in brexpiprazole pivotal programme in Agitation in Alzheimer’s progresses as planned

**Study objective**

To compare the efficacy of 2 doses of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer’s type

**Third study out of three in the pivotal programme (phase III):**

Brexpiprazole (fixed dose 2mg and 3mg) and placebo

**Primary endpoint:** Cohen-Mansfield Agitation Inventory (CMAI) total score (Week 12)

**Secondary endpoint:** Clinical Global Impression Severity of Illness (CGI-S) score

Study started in May 2018

Fast Track designation granted February 2016

1) Clinicaltrials.gov ID: NCT03548584
Brexipiprazole in pivotal programme for the treatment of agitation in Alzheimer’s disease

Alzheimer’s Disease (AD)

50 million people worldwide have dementia (Alzheimer’s is the most common cause of dementia contributing 60-70% of cases)

It is predicted that the number of people affected by dementia will almost double every 20 years

People with Alzheimer’s live an average of 8 years after their symptoms become noticeable to others

The total global societal costs of dementia are estimated to be USD 600 billion

Agitation in Alzheimer’s disease (AAD)

>20% of individuals in a community setting and >50% of nursing home residents with dementia have agitation

1.5-2m dementia patients in the U.S. with agitation / aggression

No FDA approved medication

Associated with:

Increased caregiver burden leading to increased cost to the healthcare system

Decreased functioning

Earlier nursing home placement
PTSD offers an exciting opportunity for brexpiprazole

**PTSD epidemiology**

- >8m – U.S. prevalence (2.5%-3.6%)\(^1, 2\)
- ~3m – Severe (36.6%)\(^2\)
- ~1.8m – pharmacological treatment rate (~60%)\(^2\)

**Post-traumatic Stress Disorder (PTSD)**

- ~8.6m U.S. adults affected, but ~80% estimated to be undiagnosed
- Growing economic and social burden of care
- Inadequate response with approved SSRIs - polypharmacy the norm

**PoC study\(^4\) showed…**

Combination of brexpiprazole and sertraline demonstrated improvement in symptoms of PTSD versus placebo (\(p<0.01\)) on the primary endpoint (CAPS-5 total score\(^3\))

- The efficacy supported by multiple secondary endpoints
- The overall safety and tolerability of brexpiprazole were good

---

Both studies in brexpiprazole pivotal programme in PTSD ongoing

Study objective
To evaluate the efficacy, safety, and tolerability of 12-week brexpiprazole + sertraline combination treatment in adult subjects with PTSD (n = 577 and 733)

Two studies initiated in the pivotal programme (phase III)
Brexpiprazole (fixed 2, 3mg and flexible dose up to 3mg) in combination with sertraline

Primary endpoint: Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score

Secondary endpoints: Change in Clinical Global Impression - Severity (CGI-S) score; Change in Brief Inventory or Psychosocial Functions (B-IPF) score

First study started in October 2019 and the second in November 2019

U.S. dedicated study

1) Clinicaltrials.gov ID: NCT04124614 and NCT04174170
Borderline Personality Disorder (BPD) offers an exciting opportunity for brexpiprazole

**BPD epidemiology**

- ~5m – U.S. prevalence (1.6%, but likely higher)
- ~2.4m – diagnosis rate (45%)
- ~1.7m – pharmacological treatment rate (~70%)

**Borderline Personality Disorder (BPD)**

Dysfunctions in the serotoninergic and dopaminergic systems is considered as possible causes for symptoms associated with BPD.

Pharmacotherapy focuses on key symptoms (agression, irritability, depressed mood, behavioural dyscontrol and affective dysregulation, anxiety, psychoticism and hostility) which brexpiprazole is hypothesized to address.

No drugs approved for BPD

---

**Study objective**

To evaluate the efficacy and safety of 12-week brexpiprazole for the treatment of subjects diagnosed with BPD (n = ~240) to provide a pharmacological treatment for BPD

---

**Phase II**

Brexipiprazole (flexible dose 2-3mg) and placebo

**Primary endpoint:** Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) total score (Week 12)

**Secondary endpoints:** Clinical Global Impression - Severity of Illness (CGI-S); Patient's Global Impression of Severity (PGI-S); Patient's Global Impression of Change (PGI-C) Scale; Clinical Global Impression - Improvement (CGI-I) Scale

Fast Track designation granted October 2019

Study initiated in October 2019

---

1) Clinicaltrials.gov ID: NCT04100096
Lundbeck La Jolla has access to an exciting biology platform exploring serine hydrolases starting with the endocannabinoid system.

Access to world class MAG-lipase development candidates to bolster our portfolio.

Pipeline in a drug – many potential indications.

Discovery site in U.S.

World class platform to expand to novel biological targets.

Chemical biology tool box to compliment the Lundbeck neuroscience and modality expertise.
PDE10 inhibition: A new approach to obtain a combined D₁ agonist-like effect and D₂ antagonist-like effect

**D₁ Receptor**
- Stimulator
- Inhibitor
- D₁ receptors are stimulatory GPCRs
- Dopamine at the D₁ receptor stimulates adenylate cyclase and increases cAMP
- By blocking cAMP breakdown PDE10i mimics D₁ stimulation

**D₂ Receptor**
- Stimulator
- Inhibitor
- D₂ receptors are inhibitory GPCRs
- Dopamine at the D₂ receptor inhibits adenylate cyclase and decreases cAMP
- By blocking cAMP breakdown PDE10i mimics D₂ antagonism
**Proof-of-concept study commenced in December 2018**

**Monotherapy**

Two fixed-flexible doses, once daily
- 1-2mg/day
- 3-4mg/day
- placebo

N = ~250 patients

**Primary endpoint:** Change from baseline to Week 12 in BNSS total score

Several secondary endpoints

---

*) Clinicaltrials.gov ID: NCT03793712
**) Brief negative symptom scale (BNSS)
Negative symptoms represent a major unmet medical need

Schizophrenia has three core symptoms: Positive, cognitive and negative symptoms

Negative symptoms together with impaired cognition are the major cause of the marked functional disability

Negative symptoms are thus a key contributor to the enormous costs of schizophrenia

No pharmacological treatment

40 - 50% of patients with schizophrenia are clinically stable outpatients; of those 40% experience at least two prominent negative symptoms (~20% of the total schizophrenia population)

Prevalence¹)
(major countries)

4.7m
Prevalence of schizophrenia (G7)

3.5m
Treatment prevalence (75%)

1.7m
Clinical stable outpatients (50%)

0.8m
Negative symptoms (40%)

¹) Decision Resource: Schizophrenia. Landscape & Forecast 2018
## RESEARCH & DEVELOPMENT

## Pipeline – investing for the future

<table>
<thead>
<tr>
<th>Project</th>
<th>Area</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Filing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eptinezumab (anti-CGRP mAb)</td>
<td>Migraine prevention</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>≥2021</td>
</tr>
<tr>
<td>Brexpiprazole¹</td>
<td>Agitation in Alzheimer’s disease</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>≥2021</td>
</tr>
<tr>
<td>Brexpiprazole¹</td>
<td>PTSD</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>≥2023</td>
</tr>
<tr>
<td>Brexpiprazole¹</td>
<td>Borderline Personality Disorder</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>≥2025</td>
</tr>
<tr>
<td>Lu AF11167 (PDE 10 inhibitor)</td>
<td>Schizophrenia</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>≥2025</td>
</tr>
<tr>
<td>Aripiprazole 2-month injectable</td>
<td>Schizophrenia+bipolar I disorder</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>≥2025</td>
</tr>
<tr>
<td>Lu AF82422 (alpha-synuclein mAb)</td>
<td>Synucleinopathies</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>&gt;2025</td>
</tr>
<tr>
<td>Lu AF28996 (D1/D2 agonist)</td>
<td>Parkinson’s disease</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>&gt;2025</td>
</tr>
<tr>
<td>Lu AG06466 (MAGLi)²</td>
<td>Neurology/psychiatry</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>&gt;2025</td>
</tr>
<tr>
<td>Lu AF88434 (PDE1B inhibitor)</td>
<td>Cognitive dysfunction</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>&gt;2025</td>
</tr>
<tr>
<td>Lu AG09222 (PACAP mAb)³</td>
<td>Migraine</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>&gt;2025</td>
</tr>
<tr>
<td>Lu AF87908 (Tau mAb)</td>
<td>Tauopathies</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>&gt;2025</td>
</tr>
</tbody>
</table>

¹ Acts as a partial agonist at 5-HT₁₆ and dopamine D₂ receptors at similar potency, and an antagonist at 5-HT₂₆ and noradrenaline alpha1B/2C receptors.
² MAGLi: Monoacylglycerol lipase inhibitor (“MAGlipase”).
³ PACAP: inhibits pituitary adenylate cyclase-activating polypeptide

Most advanced stage shown
Maintaining focus on our role and responsibility in society

During the recent quarter, the COVID-19 pandemic challenged the global community affecting everyone

- We have adapted our ways of working to preserve employee safety while ensuring business continuity
- Focused on maintaining stable supply of medicines to help people suffering from brain diseases
- Provided financial and medical support to eligible not-for-profit groups providing pandemic and mental health across the globe
- Expanded virtual resources for people whose mental health has been impacted
- Working with the Danish Medicines Agency on pandemic preparedness

Our focus on progressing to carbon-neutrality has not diminished

- Part of Danish Climate Partnership on Business Ambition 70%

### ESG UPDATE

<table>
<thead>
<tr>
<th>Category</th>
<th>Q1 2020</th>
<th>Q1 2019</th>
<th>Δ% y/y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy (MWh)</td>
<td>27,748</td>
<td>27,256</td>
<td>1.8%</td>
</tr>
<tr>
<td>CO2 (tonnes)</td>
<td>4,426</td>
<td>4,361</td>
<td>1.5%</td>
</tr>
<tr>
<td>Work related accidents</td>
<td>5.4</td>
<td>8.9</td>
<td>(39%)</td>
</tr>
<tr>
<td>No. Of employees (FTE)</td>
<td>5,872</td>
<td>5,442</td>
<td>7.9%</td>
</tr>
</tbody>
</table>
Commitment to the UN Global Compact Principles and to the Sustainable Development Goals (SDG) underpins our business

• Contribute to solving societal challenges where we can

Overview of our ambitions, initiatives and targets

<table>
<thead>
<tr>
<th>SUSTAINABLE DEVELOPMENT GOALS</th>
<th>LUNDBECK’S SUSTAINABILITY - 2020 TARGETS</th>
</tr>
</thead>
</table>
| SDG 3 Good health and well-being | • Engage all Lundbeck offices in local World Mental Health Day activities  
• Establish a product donation partnership |
| SDG 5 Gender equality | • Strive to maintain an overall equal gender split for people managers globally |
| SDG 8 Decent work and economic growth | • Reduce lost time accident frequency ≤ 5 |
| SDG 12 Responsible consumption and production | • Recycle 55% of the solvents used in chemical production  
• Zero environmental incidents |
| SDG 13 Climate action | • Reduce CO₂ emission by 4% in 2020 compared to 2019  
• Obtain ‘Science Based Targets initiative (SBTi)’ approval of new climate target |
| SDG 16 Peace, justice and strong institutions | • Annual Code of Conduct training completed by all employees at work globally  
• Work to increase proportion of healthcare professionals supporting disclosure of collaborations compared to the previous reporting year |

More detailed information about our sustainability policies, efforts and results is available on www.lundbeck.com
Near-term priorities

- Manage the impact from COVID-19 internally and externally
- Secure supply of medicines to patients
- Ensure strong continued momentum for the strategic brands
- Vyepti launch in the U.S., regulatory submissions and indication expansion
- Prepare to restart and accelerate clinical activities
- Continue to execute on *Expand and Invest to Grow*
SUMMARY

Readying Lundbeck for a new growth phase – 2020 and beyond

**Strategic brands - momentum continues**
- Establishing a migraine / specialty pain franchise
- Drive innovation, expansion and acceleration of pipeline

**Near-term Invigorate**
- Advance new, innovative molecules into clinical development
- Harness the potential of serine hydrolases through Lundbeck La Jolla ABPP* platform
- Launch Vyepti in migraine prevention globally
- Expand eptinezumab in additional indications
- Develop Lu AG09222 (PACAP)

**Mid-term Accelerate**
- Trintellix launched in Japan
- Rxulti launched in Europe
- New LCM studies ongoing with brexpiprazole
- Advance new, innovative molecules into clinical development
- Harness the potential of serine hydrolases through Lundbeck La Jolla ABPP* platform

**Long-term Transform**
- New LCM studies ongoing with brexpiprazole

*) Activity-Based Protein Profiling
Thank you
Continued excellence in commercial execution delivers double-digit revenue growth in all regions for the four strategic brands.
Solid volume growth in the U.S. for all strategic brands

Source: Symphony Health (ref Bloomberg)
**APPENDIX**

**Total molecule sales (gross) - USDm**

- **Abilify Maintena**: U.S. approval (Feb. 2013); EU approval (Nov. 2013)
- **Brintellix/Trintellix**: U.S. approval (Oct. 2013); EU approval (Dec. 2013); Japan approval (Sep. 2019)
- **Rexulti**: U.S. approval (Jul. 2015); EU approval (Jul. 2018); Japan approval (Jan. 2018 – NOT Lundbeck territory)

*Source: IMS*
**APPENDIX - EARLY PROJECTS**

Lu AF28996: A potentially new oral treatment for Parkinson’s patients experiencing motor fluctuations

**D\textsubscript{1}/D\textsubscript{2}-type agonists**

Known to be highly efficacious even in the later stages of Parkinson’s, but the currently available agonist (apomorphine) cannot be delivered by oral route.

Improving the treatment of fluctuating Parkinson’s patients answers a strong unmet need and is an attractive commercial target.

**Lu AF28996**

A highly potent agonist at the D\textsubscript{1}- and D\textsubscript{2}-type dopamine receptors.

Designed to solve a long-standing challenge of oral delivery of D\textsubscript{1}/D\textsubscript{2}-type agonists such as apomorphine.

Parkinson’s disease (moderate to advanced) as adjunct to L-DOPA (or monotherapy pending data).

Further expansion of patient population and symptoms (including non-motor symptoms) are being considered.

**Phase I studies\textsuperscript{1}**:

- Single- and sequential-ascending-dose of Lu AF28996 to healthy young men.
- Open-label study investigating the safety, tolerability and pharmacokinetic profile of Lu AF28996.
- Phase Ia initiated in May 2018, completed in August 2019.
- Phase Ib was planned to be initiated Q1 2020.

1) Clinicaltrials.gov ID: NCT03565094
**APPENDIX - EARLY PROJECTS**

**Lu AF82422: Potential disease modifying antibody for Parkinson’s disease**

Pathological alpha-synuclein is released to extracellular space upon cell death and can mediate seeding and aggregation of alpha-synuclein in healthy neurons\(^1\).

This process is considered to be central in the disease progression of Parkinson’s, Multiple System Atrophy and other synucleopathies\(^2\).

Lu AF82422 is able to inhibit seeding of pathological form(s) of alpha-synuclein in in vitro and in vivo models.

Has the potential to induce immune-mediated clearance of alpha-synuclein/mAb complexes.

**Pathogenesis of Parkinson’s**

**Ongoing phase I study\(^3\):**

- Healthy non-Japanese and Japanese subjects and in patients with Parkinson’s
- **Primary endpoint:** Number of patients with incidence of Treatment-Emergent Adverse Events (safety and tolerability) from dosing to Day 84
- Study initiated in July 2018

---

\(^1\) Poewe et al Nature Reviews Disease Primers vol. 3 17013 (2017) https://www.nature.com/articles/nrdp201713


\(^3\) Clinicaltrials.gov ID: NCT03611569
**APPENDIX - EARLY PROJECTS**

**Lu AG09222: Potential to build a migraine franchise in the future with early-stage PACAP\(^2\) inhibitor mAb**

**A differentiated approach to migraine prevention**

- Highly potent and selective humanized PACAP binding antibody
- Preclinical data\(^1\) indicate that PACAP\(^2\) and CGRP\(^3\) have differentiated pharmacology with respect to migraine-associated symptoms
- Potential for mono-therapy in non-CGRP\(^3\) induced migraine or combination therapy with eptinezumab

1) Loomis et al: Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate cyclase-activating peptide, JPET Fast Forward
2) Pituitary adenylate cyclase-activating peptide
3) Calcitonin gene-related peptide. Clinicaltrials.gov ID: NCT04197349
Projects with new MoAs in clinical development

**Lu AF88434**

- Potent and selective phosphodiesterase PDE1B inhibitor
- PDE1 is an intracellular enzyme responsible for the degradation of cGMP and cAMP
- cGMP is a critical intracellular signalling molecule that regulates neuronal functions like synaptic plasticity, cognitive function, neuronal survival and axonal regeneration
- FIH study* initiated in July 2019 to investigating the safety, tolerability, PK/PD properties

**Lu AF87908**

- Tau mAb
- Binding to and inhibition of pathological seeding form of Tau
- Specific and pathology directed mAb
- Retaining the capacity to mediate active clearance of Tau
- FIH study* initiated in Sep. 2019 in healthy subjects and AD patients

*) Clinicaltrials.gov ID: NCT04149860

*) Clinicaltrials.gov ID: NCT04082325
Cash flow impacted by lower EBIT and acquisitions, but solid cash generation still provides flexibility

- **Net cash flow:** Up DKK 928 million to DKK -716 million in Q1 2020 vs. Q1 2019
- FY 2020 cash flow will be negatively impacted by
  - Investments in Vyepti
  - Lower EBITDA
  - Dividend payout for 2019
- **Net debt:** Expected to amount to around DKK 6 billion (USD ~1bn) by end-2020
## Product distribution of revenue – Q1 2020 and FY 2019

<table>
<thead>
<tr>
<th>DKKm</th>
<th>FY 2019</th>
<th>FY 2018</th>
<th>Q1 2020</th>
<th>Q1 2019</th>
<th>Growth</th>
<th>Growth in local currencies</th>
<th>% of total</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abilify Maintena</td>
<td>1,961</td>
<td>1,595</td>
<td>612</td>
<td>462</td>
<td>33%</td>
<td>30%</td>
<td>13%</td>
</tr>
<tr>
<td>Brintellix/Trintellix</td>
<td>2,826</td>
<td>2,182</td>
<td>817</td>
<td>601</td>
<td>36%</td>
<td>34%</td>
<td>18%</td>
</tr>
<tr>
<td>Cipralex/Lexapro</td>
<td>2,314</td>
<td>2,257</td>
<td>722</td>
<td>619</td>
<td>17%</td>
<td>16%</td>
<td>16%</td>
</tr>
<tr>
<td>Northera</td>
<td>2,328</td>
<td>1,806</td>
<td>538</td>
<td>435</td>
<td>24%</td>
<td>20%</td>
<td>12%</td>
</tr>
<tr>
<td>Onfi</td>
<td>1,052</td>
<td>3,165</td>
<td>153</td>
<td>325</td>
<td>(53%)</td>
<td>(54%)</td>
<td>3%</td>
</tr>
<tr>
<td>Rexulti/Rxulti</td>
<td>2,270</td>
<td>1,723</td>
<td>713</td>
<td>481</td>
<td>48%</td>
<td>43%</td>
<td>16%</td>
</tr>
<tr>
<td>Sabril</td>
<td>847</td>
<td>1,342</td>
<td>177</td>
<td>254</td>
<td>(30%)</td>
<td>(33%)</td>
<td>4%</td>
</tr>
<tr>
<td>Other pharmaceuticals</td>
<td>3,100</td>
<td>3,143</td>
<td>781</td>
<td>869</td>
<td>(10%)</td>
<td>(11%)</td>
<td>17%</td>
</tr>
<tr>
<td>Other revenue</td>
<td>660</td>
<td>662</td>
<td>139</td>
<td>236</td>
<td>(41%)</td>
<td>(41%)</td>
<td>3%</td>
</tr>
<tr>
<td>Effects from hedging</td>
<td>(322)</td>
<td>242</td>
<td>(88)</td>
<td>(48)</td>
<td>-</td>
<td>-</td>
<td>-2%</td>
</tr>
<tr>
<td>Total revenue</td>
<td>17,036</td>
<td>18,117</td>
<td>4,564</td>
<td>4,234</td>
<td>8%</td>
<td>7%</td>
<td>100%</td>
</tr>
</tbody>
</table>
## Cash generation

<table>
<thead>
<tr>
<th>DKKm</th>
<th>Q1 2020</th>
<th>Q1 2019</th>
<th>FY 2019</th>
<th>FY 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash flows from operating activities</td>
<td>188</td>
<td>837</td>
<td>2,609</td>
<td>5,981</td>
</tr>
<tr>
<td>Cash flows from investing activities</td>
<td>(68)</td>
<td>(63)</td>
<td>(7,755)</td>
<td>(2,907)</td>
</tr>
<tr>
<td><strong>Cash flows from operating and investing activities (free cash flow)</strong></td>
<td>120</td>
<td>774</td>
<td>(5,146)</td>
<td>3,074</td>
</tr>
<tr>
<td>Cash flows from financing activities</td>
<td>(836)</td>
<td>(2,418)</td>
<td>4,548</td>
<td>(1,607)</td>
</tr>
<tr>
<td><strong>Net cash flow for the period</strong></td>
<td>(716)</td>
<td>(1,644)</td>
<td>(598)</td>
<td>1,467</td>
</tr>
<tr>
<td>Cash, bank balances and securities, end of period</td>
<td>2,287</td>
<td>5,014</td>
<td>3,012</td>
<td>6,635</td>
</tr>
<tr>
<td>Interest-bearing debt</td>
<td>(9,638)</td>
<td>(462)</td>
<td>(9,578)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Net cash/(net debt)</strong></td>
<td>(7,351)</td>
<td>4,552</td>
<td>(6,566)</td>
<td>6,635</td>
</tr>
</tbody>
</table>
## Balance sheet and dividend

<table>
<thead>
<tr>
<th>DKKm</th>
<th>31.03.2020</th>
<th>31.12.2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intangible assets</td>
<td>22,652</td>
<td>23,399</td>
</tr>
<tr>
<td>Other non-current assets</td>
<td>3,554</td>
<td>3,320</td>
</tr>
<tr>
<td>Current assets</td>
<td>8,661</td>
<td>9,038</td>
</tr>
<tr>
<td><strong>Assets</strong></td>
<td><strong>34,867</strong></td>
<td><strong>35,757</strong></td>
</tr>
<tr>
<td>Equity</td>
<td>14,074</td>
<td>14,554</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>12,928</td>
<td>10,923</td>
</tr>
<tr>
<td>Current liabilities</td>
<td>7,865</td>
<td>10,280</td>
</tr>
<tr>
<td><strong>Equity and liabilities</strong></td>
<td><strong>34,867</strong></td>
<td><strong>35,757</strong></td>
</tr>
<tr>
<td>Cash and bank balances</td>
<td>2,283</td>
<td>3,008</td>
</tr>
<tr>
<td>Securities</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Interest-bearing debt</td>
<td>(9,638)</td>
<td>(9,578)</td>
</tr>
<tr>
<td><strong>Interest-bearing debt, cash, bank balances and securities, net, end of year</strong></td>
<td><strong>(7,351)</strong></td>
<td><strong>(6,566)</strong></td>
</tr>
</tbody>
</table>

### Dividend (DKK)

- Dividend payout of DKK 4.10 per share for 2019, corresponding to a payout ratio of 31%
- A total of DKK 816 million and a yield of 1.6%*
- Dividend policy: Payout ratio of 30-60% from 2019

*Based on the share price of DKK 254.40
## Costs – Full year figures

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
<th>2017</th>
<th>2016</th>
<th>2019 (Δ%)</th>
<th>2018 (Δ%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>17,036</td>
<td>18,117</td>
<td>17,234</td>
<td>15,634</td>
<td>(6%)</td>
<td>5%</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>3,385</td>
<td>3,456</td>
<td>3,881</td>
<td>4,082</td>
<td>(2%)</td>
<td>(11%)</td>
</tr>
<tr>
<td>Sales &amp; Distribution costs</td>
<td>5,514</td>
<td>5,277</td>
<td>5,649</td>
<td>5,488</td>
<td>4%</td>
<td>(7%)</td>
</tr>
<tr>
<td>Administrative expenses</td>
<td>899</td>
<td>762</td>
<td>833</td>
<td>805</td>
<td>18%</td>
<td>(9%)</td>
</tr>
<tr>
<td>R&amp;D costs</td>
<td>3,116</td>
<td>3,277</td>
<td>2,705</td>
<td>2,967</td>
<td>(5%)</td>
<td>21%</td>
</tr>
<tr>
<td><strong>Total costs</strong></td>
<td>12,914</td>
<td>12,772</td>
<td>13,068</td>
<td>13,342</td>
<td>1%</td>
<td>(2%)</td>
</tr>
<tr>
<td>EBIT&lt;sup&gt;1)&lt;/sup&gt;</td>
<td>3,608</td>
<td>5,301</td>
<td>4,408</td>
<td>2,292</td>
<td>(32%)</td>
<td>20%</td>
</tr>
<tr>
<td>Core EBIT</td>
<td>4,976</td>
<td>6,158</td>
<td>5,115</td>
<td>3,477</td>
<td>(19%)</td>
<td>20%</td>
</tr>
</tbody>
</table>

### Cost Breakdown

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
<th>2017</th>
<th>2016</th>
<th>2019 (Δ%)</th>
<th>2018 (Δ%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of sales</td>
<td>19.9%</td>
<td>19.1%</td>
<td>22.5%</td>
<td>26.1%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sales &amp; Distribution costs</td>
<td>32.3%</td>
<td>29.1%</td>
<td>32.8%</td>
<td>35.1%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Administrative expenses</td>
<td>5.3%</td>
<td>4.2%</td>
<td>4.8%</td>
<td>5.1%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>R&amp;D costs</td>
<td>18.3%</td>
<td>18.1%</td>
<td>15.7%</td>
<td>19.0%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>EBIT margin</strong></td>
<td>21.2%</td>
<td>29.3%</td>
<td>25.6%</td>
<td>14.7%</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<sup>1)</sup> Includes Other operating items, net
Lundbeck has seen strong progress against *Expand and Invest to Grow* strategy announced in February 2019

- Solid growth across strategic brands
- Global footprint with growth in all regions of the world
- Two acquisitions made in 2019 expand the indications within neuroscience and add to the pipeline across all phases of development
  - Lundbeck La Jolla Research Center created: Establishing a strong platform for innovation
  - Lundbeck Seattle BioPharmaceuticals builds antibody capabilities
- Long-standing reputation with patient communities and physicians
- Deep scientific heritage and capabilities in CNS
- Demonstrated track record of partnering relationships
- Solid, stable cash generative base business
- Solid profitability while investing in future growth
INVESTOR RELATIONS

For more information, please contact Investor Relations

- Listed on the Copenhagen Stock Exchange since 18 June 1999
- Deutsche Bank sponsored ADR programme listed on NASDAQ (U.S. OTC) effective from 18 May 2012
- For additional company information, please visit Lundbeck at: www.lundbeck.com

Number of shares: 199,136,725
Treasury shares: 435,019 (0.22%)
Insider holdings: 130,339 (0.07%)
Classes of shares: 1
Restrictions: None
ISIN code: DK0010287234
Ticker symbol: LUN DC/LUN.CO (Bloomberg/Reuters)

ADR programme: Sponsored level 1
ADR symbol: HLUYY
Ratio: 1:1

IR contact

Palle Holm Olesen
VP; Head of Investor Relations
Mobile: +45 3083 2426
palo@lundbeck.com or polesen3@bloomberg.net

Financial calendar

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6M 2020</td>
<td>13 August 2020</td>
</tr>
<tr>
<td>9M 2020</td>
<td>3 November 2020</td>
</tr>
<tr>
<td>FY 2020</td>
<td>February 2021</td>
</tr>
<tr>
<td>Q1 2021</td>
<td>May 2021</td>
</tr>
</tbody>
</table>